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Abstract
The wearable cardioverter-defibrillator (WCD) is a rechargeable external device
that can be worn under the clothing all day long and protects the wearer from
potentially life-threatening ventricular tachyarrhythmias. When a dangerous
arrhythmia is detected, the WCD can deliver high-energy shocks. The WCD has
been shown to be effective in accurately detecting and appropriately treating ven-
tricular tachycardia (VT) and ventricular fibrillation (VF). It is intended for tem-
porary use as a bridge to an implantable cardioverter-defibrillator (ICD), heart
transplantation, or left ventricular assist device; patients with heart failure with
reduced ejection fraction may benefit from the WCD while their condition
improves. It can be used temporarily after explant of an ICD until reimplantation is
deemed possible. In select patients with myocardial infarction, a WCD may be
useful during the immediate period after infarction. It is indicated for use when a
permanently implanted ICD must be explanted because of infection; the patient can
use the WCD until the infection resolves, and a new ICD can be implanted. The role
of the WCD is emerging as an important therapeutic option to protect patients at
elevated risk of sudden cardiac death (SCD).
Keywords: arrhythmia, cardiomyopathy, heart failure, heart transplantation,
implantable cardioverter-defibrillator, sudden cardiac death,
wearable cardioverter-defibrillator (WCD)
1. Introduction
Sudden cardiac death (SCD) is mainly due to ventricular tachyarrhythmias even
though bradycardia may occur. The population at risk for SCD is heterogeneous and
includes those whose risk is based on a transient arrhythmia-provoking electrical
event, structural heart disease, a channelopathy, heart failure, cardiomyopathy, or
other underlying conditions [1]. For patients at elevated risk for potentially life-
threatening ventricular tachyarrhythmias but with a transient contraindication for
an implantable cardioverter-defibrillator (ICD) therapy, the wearable cardioverter-
defibrillator (WCD) is an important therapeutic option (LifeVest 4000®, Zoll,
Pittsburgh, Pennsylvania, USA). The external vest delivers high-energy rescue
therapy in the event a ventricular tachyarrhythmia is detected along with electro-
gram storage and remote monitoring [2]. First introduced to market in 2001, the
WCD is intended for short-term use, typically for a few months [3].
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2. The WCD and its function
Currently, there is only one WCD, the LifeVest 4000®, and no other similar
products are on the market. The WCD weighs 800 g and is available in a range of
sizes with adjustable straps and an elasticized belt to fit snugly next to the skin
under clothing (Figure 1). The WCD has three pad-style electrodes for defibrilla-
tion and four more electrodes for arrhythmia detection (sensing). It is equipped
with a battery-powered defibrillation unit capable of generating several high-
energy shocks. When the WCD prepares to deliver a shock, it delivers a small
amount of gel to the skin at each electrode, and a biphasic waveform of 75 or 150 J
is delivered [4].
The WCD detects arrhythmias using an algorithm of heart rate (including rate
stability and onset of arrhythmia) and waveform morphology. In the presence of
noise or when a waveform template is not available, the detection function can
work using rate alone. Once an arrhythmia is detected, the device signals the patient
for about 30 s, allowing the wearer to abort the shock by manually depressing two
response buttons. If the rate drops below the detection threshold during this 30-s
waiting period, the detection is delayed or the shock prevented, depending on
whether the slower rate was brief and temporary or persisted [5]. The WCD offers
programmable parameters in that the ventricular fibrillation (VF) zone can be set
between 120 and 250 beats per minute (bpm) and the ventricular tachycardia (VT)
zone can be programmed from 120 bpm to the lower bound of the VF zone [6].
The clinician may also program the time from arrhythmia detection to therapy
delivery from 60 to 180 s for the VT zone and 25 to 40 s for the VF zone [5].
TheWCD is rechargeable and comes with two lithium-ion batteries. One battery
is used at all times in the device, while the other may be charged in about 3.5 h using
a proprietary charging station. Battery life is approximately 2 days, but even if the
battery signals the patient that it is getting low, there is usually sufficient charge
retained for 10 shocks of 150 J each. During an arrhythmic episode, the WCD will
deliver up to five shocks. If the arrhythmia persists, the device detects again and
repeats the cycle until the rhythm is converted or the battery is exhausted [5]. Once
the WCD delivers therapy, it should be replaced.
Figure 1.
The WCD (LifeVest 4000® from Zoll) is worn like a vest and is powered by a rechargeable battery, capable of
delivering high-energy shocks to convert a potentially life-threatening ventricular tachyarrhythmia. Art by Todd
Cooper.
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Patients are given a transmitter which can transmit data from the WCD directly
to the clinic via a secure server. Remote transmissions do not require any patient
intervention. Like cardiac implantable electronic devices, the WCD can be
programmed to send out alerts when specific triggering events occur. The remote
monitoring system records the number of hours per day that the patient wears the
WCD, and the patient can activate the device to record an electrogram in the event
of symptoms. While the WCD will attempt to make a daily remote transmission, if
this is not possible, data transmission should occur at least once a week, and
monthly in-clinic visits are recommended for WCD patients [5]. Reports from the
WCD are shown in Figures 2 and 3.
3. Guidelines for the WCD
The American College of Cardiology, American Heart Association, and Euro-
pean Society of Cardiology (ACC/AHA/ESC) 2006 guidelines for the management
of patients with ventricular arrhythmias and the prevention of sudden cardiac death
was the first society-based recommendation for the use of WCD in patients at
transient high risk for VF, such as patients waiting for heart transplant; patients at
high risk following an acute myocardial infarction or invasive cardiac procedure;
and patients whose ICD had to be temporarily explanted, for example, because of
an infection [7]. The International Society for Heart and Lung Transplantation
Figure 2.
The wear time: report on the WCD.
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guidance made the WCD a Class I indication for Status 18 patients awaiting trans-
plant at home [8]. In 2009, the Heart Rhythm Society expert consensus
recommended that the WCD be considered as an alternative treatment for patients
who needed early ICD revision following device explant in the setting of suspected
continuing infection [9]. In 2013, the ACC/AHA guideline stated that the utility of
the WCD in high-risk patients in the first 4 to 6 weeks after myocardial infarction
was being investigated [10]. The European Heart Rhythm Association, Heart
Rhythm Society, and Asia Pacific Heart Rhythm Society (EHRA/HRS/APHRS)
Expert Consensus on Ventricular Arrhythmias stated that patients with heart failure
Figure 3.
Report from the WCD about a tachycardia that was detected but did not require therapy delivery.
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with reduced ejection fraction after a myocardial infarction (with or without revas-
cularization) may benefit from WCD use in weeks to months until recovery [11].
Many patients who might be potential WCD candidates are not routinely included
in clinical trials, and the HRS/ACC/AHA Expert Consensus Statement of 2014
suggested that the WCD may be considered as a “bridge to ICD” in certain patients
[12]. The following year, in 2015, ESC guidelines suggested that the WCD might be
used in patients with transiently impaired LV function, naming certain specific
conditions such as myocardial infarction, peripartum cardiomyopathy, and myo-
carditis, and in patients awaiting heart transplantation or a left ventricular assist
device [13].
In 2016, the AHA issued a science advisory about the WCD which was endorsed
by the HRS [14]. Among their key concepts: they viewed the WCD as a temporary
means for preventing arrhythmic death without the need of bystander response;
despite limited evidence from randomized controlled trials, observational data sup-
port the notion that the WCD can detect and terminate ventricular tachyarrhyth-
mias; and the use of a WCD is reasonable when there is a clear ICD indication and a
current, transient contraindication to ICD implantation. According to this advisory,
the role of a WCD is less clear when the risk of arrhythmias is transient, but a WCD
still may be appropriate. The most controversial use of the WCD is in patients in
the early recovery phase after myocardial infarction or with a newly diagnosed form
of nonischemic cardiomyopathy. Many of these patients will not need a permanent
ICD but will experience a period of time when they are at increased risk of SCD.
Evidence for use of the WCD was C-level (expert opinion) and may be
summarized as:
• The use of WCD is reasonable when there is an indication for an ICD, but a
transient contraindication or interruption in ICD care (such as infection)
temporarily prevents implantation (Class IIa).
• The use of WCD is reasonable as a bridge to more definitive therapy, such as
heart transplant (Class IIa).
• The use of WCD may be reasonable if there is concern about an elevated SCD
risk that is expected to resolve over time or with treatment, for example,
ischemic heart disease following revascularization or nonischemic
cardiomyopathy being initiated on guideline-directed medical therapy
(Class IIb).
• TheWCDmay be appropriate as a bridge therapy when patients are at elevated
risk for SCD in cases where an ICD would reduce the risk of SCD but not
improve overall survival, such as within 40 days following acute myocardial
infarction (Class IIb).
• WCDs should not be used when the risk for potentially life-threatening non-
arrhythmic causes is expected to exceed the risk of ventricular arrhythmias,
especially in those situations where longevity is not expected to exceed
6 months (Class III).
4. Clinical trials and other evidence
There are many observational studies about the use of theWCD, but to date only
one large randomized clinical trial has been published, the Vest Prevention of Early
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Study description Appropriate therapy Inappropriate therapy Wear time Comments
Acute myocardial infarction
Barraud et al. 24 consecutive
patients with LVEF <30% and
recent myocardial revascularization
Two VT occurred (8.3%); one
terminated spontaneously, and one
was successfully treated
None Mean 3.0  1.3 months duration
Daily wear time 21.5 hours/day
The WCD offered life-saving
intervention for one patient
Kondo et al. 24 patients with
myocardial infarction
Two patients (8.3%) received
appropriate shock; both first shocks
were successful
None Median duration of WCD therapy
was 33 days (range 20–67 days)
Median daily wear time 23.1 h/day
One patient excluded because of
irregular use of WCD
In total, 58% went on to get ICD.
Ejection fraction improved over
baseline (p < 0.01) with 50%
having an ejection fraction >35%
Two patients (8.3%) died of fatal
but non-arrhythmic events within
3 months
Controlled studies
Olgin et al. VEST 2302 patients
with myocardial infarction with
ejection fraction ≤35%
1524 in WCD arm 778 controls
20 patients (1.3% of WCD group) Nine patients (0.6% of WCD
group)
Mean follow-up was
84.3  15.6 days
Wear time for WCD patients was
median 18.0 h/d (3.8–22.7) with
decreasing wear time over course of
study
Arrhythmic death occurred in 1.6%
and 2.4% of WCD and controls,
respectively (not significant)
All-cause mortality rates were 3.1%
and 4.9% for WCD and controls,
respectively (p = 0.04)
Of the 48 WCD patients who died,
only 12 were wearing the WCD at
time of death
Heart failure
Barsheshet et al. 75 heart failure
patients prescribed a WCD in an
observational study at 2 centers,
SWIFT
Eight arrhythmic events occurred in
6.6% of patients (n = 5), all
successful
None Median wearing duration was
59 days, 80% of patients wore the
WCD more than 50% of the day
At the end of study, 28% received an
ICD
Duncker et al. PROLONG study
156 patients with ejection fraction
≤35% prescribed WCD for
3 months and then re-evaluated
Eleven patients received a total of 12
appropriate shocks
None Cumulative 42.7 patient-years of
wear time; mean time per patient
was 101  89 days
Wear time 21.7  4.0 h/day
48/156 discontinued therapy before
3 months (noncompliance, early
improvement of ejection fraction,
ICD implanted, etc.)
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Study description Appropriate therapy Inappropriate therapy Wear time Comments
33% of patients improved within
3 months to ejection fraction >35%
Heart transplantation
Opreanu et al. 121 patients awaiting
heart transplantation
National registry based on
convenience sample
55% NICM, 17% ICM, 27% mixed
32% were NYHA Class III and 34%
Class IV
Seven patients (6%) Two patients (1.7%) Median wear time 39 days
Median daily use 20 h/day
Eleven patients (9%) died in the
study
Hemodialysis
Wan et al. 75 hemodialysis patients
with a history of SCA
75 patients (100%) experienced at
least 1 SCA event while wearing the
WCD
84 total events
136 total shocks delivered
Not reported Mean duration of wear
62.9  73.1 day (2–308 days)
Mean daily wear 18.9  4.6 h/day
Among patients with shockable
rhythms, 30-day survival rate was
63.0%
Infected device
Ellenbogen et al. 8058 patients who
had an ICD removed for infection
and used WCD as bridge to
reimplant
334 patients (4%) experienced 406
VT/VF events, of which 348/406
(86%) were treated by WCD, all
successfully
54 patients aborted shocks for
arrhythmias that resolved
spontaneously
12-month cumulative event rate
10%
159 patients (2%), no associated
deaths
Median wear duration 53 days
(25–94)
Daily wear time not reported
Risk of VT/VF was highest in initial
weeks after ICD removal at 0.9%,
0.7%, and 0.7% for first, second, and
third weeks, respectively
30-day post-event survival rate was
81% overall
80% of patients in this study got an
ICD
Observational studies from a single center
Bhaskaran et al.
Eight WCD patients
None None Median duration 77 days
Mean daily wear 23.4  0.6 h/day
1/8 patients in the study were
noncompliant with WCD
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Study description Appropriate therapy Inappropriate therapy Wear time Comments
Erath et al. 102 WCD patients Four patients (3.9%) Two patients (2.0%), both due to
SVT
Median duration 54 days
Median daily wear 23 h/day
55% received an ICD
Naniwadekar et al. 140 WCD
patients
32% ICM, 46% NICM
85.9% African-Americans
Two patients (1.4%) received a total
of two appropriate shocks
Two patients (1.4%) received a
total of four inappropriate shocks
(two SVT, two artifacts)
Median duration 43 days (7–
83 days)
Mean daily wear time 17.3  7.5 h/
day
Seven patients died
32% received an ICD
Roger et al. 105 consecutive
patients with newly diagnosed ICM
or NICM and ejection fraction
≤35%
Five patients (4.8%) None Mean duration of wear
68.8  50.4 days
Mean wear time 21.5  3.5 h/day
At the end of WCD wear, 54.8% of
ICM and 48.8% of NICM patients
indicated for primary prevention
ICD
Sasaki et al. Nine patients at risk for
SCD
One patient (11.1%) None Median duration of use 21 days [7–
31]
Median wear time 23.7 h/day (23.6–
23.9)
One patient died of worsening heart
failure
67% received an ICD
Pediatric
Spar et al. 455 patients (age 3–
17 years)
Six patients (1.3%) received a total
of 13 shocks
Two patients (0.4%) Median duration of use 33 days (1–
999)
Median wear time 20.6 h/day (0.3–
23.8)
Seven patients died, none of whom
were wearing the WCD at time of
death
Psychological aspects
Weiss et al. 123 WCD patients from
a multicenter registry administered
several surveys
NA NA NA (study followed patients for
6 weeks)
Depressive symptoms decreased
from 21% at baseline to 7% after
6 weeks of using the WCD
Anxiety decreased from 52% at
baseline to 25% at week 6
Registries
Chung et al. National postmarket
registry
Retrospective analysis
First shock success was 100%
(75/75) for unconscious VA and
Inappropriate shocks occurred in
1.9% of patients in 4788 months of
use, or 1.4% per month
Mean duration of wear
52.6  69.9 days (range 1–
1590 days)
14.2% of patients discontinued
WCD
Overall survival rate was 99.2% but
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Study description Appropriate therapy Inappropriate therapy Wear time Comments
3569 WCD patients
Compared against Social Security
Death Index
99% (79/80) for all VA
89.5% survival of VA events
Multiple reasons for inappropriate
shock. Some of these shocks could
have been aborted by patients, but
patients did respond
Median daily wear time was 21.7 h/
day
52% of patients wore WCD >90%
of day
no significant difference compared
to first ICD implant patients
Daimee et al. 1732 grouped as older
(≥65, n = 722) and younger
(<65 years, n = 1010)
Older patients had higher event
rates per 100 patient-years for
sustained VT and VF (32.0 vs. 9.8,
(p = 0.027)
Older patients, especially those with
ICM were more likely to have VT/
VF treated with shock (6.9 vs. 2.4,
p = 0.034)
Not reported except as being
“rare”
Older patients had significantly
longer wear times (median 22.8 h/
day vs. 22.3 h/day p < 0.001)
Younger patients with NICM had
higher event rates per 100 patient-
years for atrial arrhythmias (150.0
vs. 74.9, p = 0.055)
Older patients were more likely to
get an ICD after WCD (41.8% vs.
36.5%, p = 0.034)
Kutyifa et al. 3195 (805 with ICM,
927 with NICM, 268 with
congenital heart disease)
WEARIT-II Registry
41 patients had 120 episodes of
sustained VT, of whom 54%
received an appropriate shock
0.5% of patients got an
inappropriate shock
Median duration of wear was
90 days
Median wear time 22.5 h/day
At the end of WCD use, 42% got an
ICD; most frequent reason not to get
an ICD was improved ejection
fraction
Lamichhane et al. 220 WCD
patients in manufacturer’s
postmarket registry of individuals
who wore the WCD > 1 year
33.2% of the patients were African-
Americans
4.1%
A total of 13 sustained VT episodes
with 92.3% success rate (12/13
shocks)
3.6% Mean duration was 451  290 days
Median wear time 20.4 h/day (15.5–
22.9)
Two patients died (one refractory
VT and one bradycardia
transitioning to asystole), and 59%
of patients stopped using the WCD
before the study ended, either
because they got an ICD, their
condition improved, they had
another intervention (transplant),
or other reasons
Retrospective analyses
Bossory et al. 201 patients from 1
center prescribed a WCD with
1 year follow-up
Five patients (2.5%), nine shocks One patient (0.5%), SVT Mean duration was 63  53.7 days
Mean wear time 23.0  0.62 h/day
79% of WCDs were prescribed by
clinicians who were not EPs
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Study description Appropriate therapy Inappropriate therapy Wear time Comments
Dillon et al. 2105 WCD patients in a
retrospective analysis of
arrhythmia detection
1.58 appropriate shocks per 100
patient-months
54 total appropriate shocks
0.99 inappropriate shocks per 100
patient-months
34 total inappropriate shocks,
most due to interference (47.1%)
Data for 1 year were analyzed
Median duration of use was 36 days
(3–365)
Median wear time 21.3 h/day (0–
23.9)
Most frequent reason for wearing
the WCD was myocardial
infarction, but study included
several indications
Ellenbogen et al. population came
from 234 consecutive in-hospital
episodes of VT/VF in 173 in-
hospital patients who had a WCD
for primary prevention, history of
VA, or other reasons, including
device explant; 40% had a history
of myocardial infarction
100% had an appropriate shock
68% occurred during weekdays, and
55% of events happened in the
daytime
Not reported Median follow-up 6 days while
patients were in the hospital
Most VA occurred in unmonitored
units, the ICU, and the ED
24-h survival following therapy
delivery was >90%
Quast et al. 79 WCD patients Two patients (2.6%) for annual rate
of 13.6%
One patient (1.3%) for annual rate
of 6.7%
Median duration 73 days (50.0–
109.8)
Median daily wear time 23.3 h/day
(22.6–23.7)
In 52.2% ejection fraction improved
enough that ICD implant was not
necessary
Salehi et al. 127 patients with CM
and self-reported excessive alcohol
use
Seven patients (5.5%) had nine
sustained VT episodes, 100%
successful conversion
Not reported Median duration 51 days
Median wear time 18.0 h/day
11 patients (8.6%) died during the
100 days of follow-up, but no deaths
were caused by WCD shock failure
or undersense
Singh et al. 639 WCD patients ICM
and NICM
None for NICM patients
Six ICM patients (2.2%), of whom
five survived the shock and four
survived to hospital discharge
Three NICM patients (1.2%)
0.7% of ICM
Mean duration 61 days (25–102)
Mean daily wear 22 h/day
Uncontrolled studies
Beiert et al. 114 patients
ICM (31.6%)
NICM (45.6%)
Congenital heart disease (5.3%)
6.1% (no NICM patients were
shocked)
One patient had an appropriate but
ineffective shock and was externally
defibrillated
64 patients (56.6%) were signaled
inappropriately for a shock,
almost all due to artifacts. All
shocks were aborted by the
Median duration 52.0 days (range
25–90)
Daily wear time 23.1 h/day
(19.0–23.8)
One patient in this study died of
asystole
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Study description Appropriate therapy Inappropriate therapy Wear time Comments
Infected device removal (11.4%)
and others
patients, no inappropriate shocks
delivered
Feldman et al.
WEARIT (n = 177) and BIROAD
(n = 112) studies
WEARIT patients had symptomatic
heart failure and ejection fraction <
30%
BIROAD patients had acute
myocardial infarction and were in
waiting period of 30–40 days
before an ICD could be implanted
Eight appropriate shocks of which
75% were successful
The two unsuccessful shocks were
deemed related to improperly
placed electrodes
Six inappropriate shocks (0.67%
unnecessary shocks/month)
Mean duration of use was
3.1 months (2.6 for BIROAD and
3.4 for WEARIT groups,
respectively)
Daily wear time not reported
12 patients died
(5 of whom were not wearing WCD,
and 1 wore it improperly)
68 patients dropped out of study for
adverse events or discomfort
wearing the WCD
Wassnig et al. 6043 WCD patients 94 patients (1.6%) were shocked
Incidence rate 8.5% (95% CI, 6.7–
10.7) per 100 patient-years for men
and 7.9% (95% CI, 4.8–12.3) for
women
94% success rate
26 patients (0.4%), incidence 2.3
(95% CI, 1.5–3.4) per 100 patient-
years
In 10 cases, the reason was SVT
Median duration varied from 49 to
66 days
Median daily wear varied from 22.7
to 23.5 h/day
Patients with explanted ICDs had
higher average rates of shock (19.3
per 100 patient-years, 95% CI, 12.2–
29.0)
Zylla et al. 106 real-life cases taken
from 2010 to 2016
One patient (0.94%) shocked for
VF, successful
Two patients (1.9%)
12.3% had an average of >1
inappropriate shock alarms per
day (shocks aborted)
Median duration of wear 58.5 days
Mean wear time 22.7 h/day
Younger patients (≤ 50 years) less
compliant
17% discontinued therapy for
various reasons: discomfort,
frequent alarms, reimbursement
problems, technical issues
AMI, acute myocardial infarction; CI, confidence interval; CM, cardiomyopathy; EP, electrophysiologist; ICD, implantable cardioverter-defibrillator; ICM, ischemic cardiomyopathy; NICM, nonischemic
cardiomyopathy; NYHA, New York Heart Association; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SVT, supraventricular tachycardia; VA, ventricular arrhythmia; VF, ventricular fibrillation;
VT, ventricular tachycardia; WCD, wearable cardioverter-defibrillator.
Table 1.
An overview of the main uses of the WCD, therapy deliveries, and key findings [15, 17–44].
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Sudden Death (VEST) study (n = 2302) [15]. All patients had had a recent myocar-
dial infarction and a left ventricular ejection fraction ≤35%; some but not all
patients had undergone revascularization. Patients were randomized into two
arms: guideline-directed medical treatment (control) or a WCD. In the first
90 days after myocardial infarction, the WCD did not result in a lower rate of
arrhythmic death, but total mortality was lower in the WCD group (3.1% vs.
4.9%, p = 0.04, uncorrected) [15]. Despite the fact that the VEST study did not
result in a lower rate of arrhythmic death for WCD patients, there are important
aspects of this study that deserve deeper scrutiny. Unwitnessed arrhythmic death
is difficult to ascertain, and five of the nine VEST subjects deemed to have died
due to an arrhythmia were wearing the WCD at the time, and the WCD showed
no evidence of a tachyarrhythmia. Since arrhythmic death is rare, even a small
number of misinterpretations in a study like this may skew results. Moreover, the
study was designed assuming patients would wear the WCD at least 70% of the
time, and compliance dropped as the study progressed. Since fewer patients
wearing the WCD died, it has been argued that there was not a single active
treatment group in the study (WCD group) but rather two: patients randomized
to the WCD group broken down into those who wore the WCD and those who did
not [16]. Of the patients in the WCD arm of the study who died, 75% were not
wearing the WCD at the time [15].
Early after the WCD was first cleared to market, an observational study called
the Wearable Defibrillator Investigative Trial (WEARIT) enrolled 177 ambulatory
patients who had New York Heart Association (NYHA) functional Class III or IV
heart failure and an ejection fraction <30%. It was subsequently combined with a
similar observational study, the Bridge to ICD in patients at risk of sudden arrhyth-
mic death (BIROAD), which enrolled patients who had an AMI and needed bridge
therapy for up to 3 months (n = 112). In 901 patient-months, the mean duration of
wear was 3.1 months. Among the WEARIT patients, there were two appropriate
and successful therapy deliveries in the same patient several days apart, and there
were four appropriate, successful therapies delivered in two of the BIROAD
patients. Two unsuccessful therapy deliveries occurred, both of which involved the
improper wear of the WCD. Altogether, 12 patients died over the course of the
study, none of whom were wearing the WCD at the time. Over the 901 patient-
months, there were 6 inappropriate therapy deliveries in 6 patients (0.7% per
month) [17].
The WEARIT-II Registry enrolled 2000 patients, of whom 805 were diagnosed
with ischemic cardiomyopathy, 927 with nonischemic cardiomyopathy, and 268
with congenital heart disease [18]. During the study, 41 patients experienced a total
of 120 episodes of VT, of whom 54% received an appropriate shock. Inappropriate
shocks occurred in 0.5% of patients. Many of the patients in WEARIT-II had
improved their ejection fraction over the course of time they wore the WCD, and at
the end of WCD treatment, only 42% got an ICD.
The Study of Wearable Cardioverter Defibrillator in Advanced Heart-Failure
Patients (SWIFT) was a nonrandomized prospective study at two centers evaluat-
ing the use of the WCD in 75 patients hospitalized with advanced heart failure
symptoms and LV dysfunction. Patients wore the WCD for 3 months after
hospital discharge. Two-thirds of the patients (66%) had nonischemic
cardiomyopathy. Eight arrhythmic events occurred in five patients, all successfully
terminated by the WCD. No inappropriate therapies were delivered, and no
patients died in the course of the study. When the study concluded, 28% were
implanted with an ICD [19].
A summary of these trials appears in Table 1.
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5. Patient populations
5.1 Transient contraindication for an ICD
One of the main reasons for WCD use is ICD system infection, which poses a
clinical challenge in that the best course of action is to extract the device and lead(s),
submit the patient to a course of antibiotic therapy, and then replace the ICD system
with a new device [7, 9, 45]. The rate of infections associated with cardiac implant-
able electronic systems continues to increase, even at high-volume centers [46].
Antimicrobial therapy may last 10–14 days or longer, depending on the nature of the
infection and the patient’s response. During this time, the patient is without an ICD.
Leaving the ICD in place while treating an infection is associated with a high mortal-
ity rate (31–66%) [47, 48], but removing the device also increases the patient’s
mortality rate, albeit from 8–27% [49–51]. Thus, the clinician faces three challenges: if
the device is replaced too early, the patient risks re-infection; if the patient is deprived
of the device too long, there is a risk for potentially life-threatening arrhythmias; and
placing the patient under close monitoring in the hospital or a long-term care facility
is cost prohibitive and deleterious to the patient’s quality of life. In such cases, the use
of a WCD can be a valuable interim solution for arrhythmic rescue.
In a study of 97 ICD patients whose devices had to be explanted for infection,
patients were prescribed a WCD for the mean antimicrobial treatment course of
21 days. As they recovered from infection, two patients experienced a total of four
VT episodes, all of which could be successfully treated [52]. In a retrospective
analysis of 8058 patients who received a WCD from 2002 to 2014 when an infected
ICD was removed, 4% experienced ventricular tachyarrhythmias, and the rate of
arrhythmic episodes was greatest in the first 3 weeks after device explantation (0.9,
0.7, and 0.7%, respectively), and the risk for ventricular tachyarrhythmias after
device removal was 4% during the first 2 months and 10% at 1 year [25].
5.2 Bridge to cardiac transplantation/left ventricular assist device
Heart transplantation or the use of a left ventricular assist device is the only
potentially long-term therapeutic option for some patients, but during the waiting
period, patients are at high risk for dangerous arrhythmias and may have other
comorbid conditions as well. In a study of 121 patients prescribed with the WCD
while waiting to receive a donor heart (mean 127 days), 7 patients (5.8%) were
shocked appropriately, and all survived [23]. Two inappropriate therapy deliveries
occurred deemed to be caused by rapid ventricular response to atrial fibrillation. In
this study, two patients died of asystole during the waiting period; asystole is not
treated by the WCD because it lacks a pacing capability [23].
5.3 Low ejection fraction in reimbursement-mandated waiting period
In the USA and other parts of the world, patients with an ejection fraction ≤35%
may be required by reimbursement authorities and guidelines to wait out a specific
period of time before an ICDmay be implanted; these time periods range from 30 to
90 days. This includes patients with cardiomyopathy.
5.4 NYHA Class IV heart failure
This group of patients meets the requirements for Class IV heart failure but is
not otherwise indicated or qualified to receive an ICD. Some of these patients may
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be waiting for cardiac transplantation, while others may be contraindicated for ICD
implant for other reasons (frailty, comorbidities, patient refusal, and so on). The
Study of Wearable Cardioverter Defibrillator in Advanced Heart-Failure Patients
(SWIFT) was a prospective study of 75 advanced heart failure patients at 2 centers.
All patients had low ejection fraction (21.5  10.4% at baseline), were prescribed a
WCD, and were followed up for 3 months. In the SWIFT study, 66% of patients had
nonischemic cardiomyopathy. Over the course of the study, eight arrhythmic
events occurred in five patients, including three episodes of nonsustained VT and
one episode of polymorphic VT; all episodes were appropriately treated. No patient
in the study received inappropriate therapy delivery. At the end of the study, 28%
of patients went on to permanent device implantation, and the cumulative mortal-
ity rate at 3 years in this population was 21% for patients with nonischemic cardio-
myopathy compared to 21% for those with ischemic cardiomyopathy [19].
5.5 Ischemic and nonischemic cardiomyopathy
Patients with ischemic cardiomyopathy may be indicated for a primary preven-
tion ICD if they have an ejection fraction ≤35% and NYHA functional Class II or III
or if they have an ejection fraction ≤30% with NYHA Class I [53]. Nonischemic
cardiomyopathy covers a range of conditions that may include inflammatory, toxic,
metabolic, genetic, or autoimmunological processes, and arrhythmic activity,
including SCD, may be one of the first symptoms of nonischemic cardiomyopathy
[5, 13]. Such patients typically fall into the reimbursement-mandated waiting
period before a primary prevention ICD can be implanted, and many patients with
recent-onset cardiomyopathy recover left ventricular ejection fraction and even
experience reverse remodeling to the point that ICD implantation is unwarranted
[5]. In cardiomyopathy patients, it is not clear if and how long patients should wait
before ICD implantation is either deemed reasonable or unnecessary [5]. Ischemic
cardiomyopathy patients may have higher rates of events than nonischemic cardio-
myopathy patients [42]. Pharmacological therapy for cardiomyopathy may also
improve the ejection fraction, and the WCD may be helpful as medical therapy is
optimized [53].
In a retrospective single-center study of patients from June 2004 to May 2015,
focus was placed on patients with newly diagnosed cardiomyopathy (254
nonischemic and 271 ischemic) [41]. Patients wore the WCD for a median of 61 days
(interquartile range 25–102 days) and for a median of 22 h/day (17–23 h). The study
produced 56.7 patient-years of data for nonischemic cardiomyopathy patients, during
which no patients got appropriate shocks, but 1.2% (n = 3) were shocked inappropri-
ately. There were 46.7 patient-years of data for ischemic cardiomyopathy, where
2.2% (n = 6) were shocked appropriately and two inappropriately (0.7%) [41].
5.6 Acute myocardial infarction
The role of defibrillation has been controversial in acute myocardial infarction
(AMI) patients since the defibrillator in acute myocardial infarction trial
(DINAMIT) reported that early ICD implantation failed to confer a mortality ben-
efit in this arrhythmia-rich population [54]. Current guidelines recommend that
following myocardial infarction, patients with compromised left ventricular func-
tion do not receive an ICD for a 3-month to 40-day waiting period, whether or not
they have been revascularized [53]. In the weeks immediately following a myocar-
dial infarction, patients are vulnerable to a number of potentially lethal conditions,
many unrelated to ventricular tachyarrhythmias, so that the mortality rate for
myocardial infarction patients with or without an ICD is roughly the same (7.2% for
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both, assuming linear mortality rates in the first 3 months, based on DINAMIT
study data) [54]. This imposes a “waiting period” on myocardial infarction patients
before a device may be implanted and during which time they may be especially
vulnerable to SCD. For many patients and clinicians, this creates a tension between
abiding by evidence-based guidelines and meeting reimbursement requirements yet
still providing reasonable means to rescue post-AMI patients from SCD [6]. The
WCD has been proposed as an interim device for this population during this waiting
period before a permanent ICD may be implanted. Further complicating this pic-
ture is the fact that some myocardial infarction patients will recover left ventricular
function in the weeks following their heart attack to the point that they do not
require an ICD at all. Thus, it may be argued that for these patients, the use of the
WCD may be to provide possible rescue during recovery from the myocardial
infarction and to avoid unnecessary ICD implantation [6].
It has been observed that myocardial infarction patients prescribed a WCD and
shocked appropriately and successfully to convert a ventricular tachyarrhythmia
nevertheless have high mortality rates. While this remains to be elucidated, it
suggests that either ventricular tachyarrhythmias in the immediate aftermath of a
heart attack are indicative of poor outcomes or the arrhythmia and/or the rescue
shock has a destabilizing effect on the patient [55]. The Valsartan in acute myocar-
dial infarction trial (VALIANT) evaluated 14,609 myocardial infarction patients
with low ejection fraction for SCD. VALIANT reported myocardial infarction
patients with an ejection fraction ≤30% had a mortality of 2.3% per month in the
first 30 days after the myocardial infarction (and that 83% of all patients who died
of sudden unexpected death died within the first 30 days of hospital discharge).
Every decrease of 5% in the ejection fraction was associated with a 21% increase in
SCD risk in the first 30 days after myocardial infarction [56].
The Vest Prevention of Early Sudden Death (VEST) trial found that in myocar-
dial infarction patients with low ejection fractions (≤35%), the WCD did not sig-
nificantly reduce arrhythmia-associated deaths compared to the control group who
did not have a WCD [15]. The rates of arrhythmic death were 1.6% in the WCD and
2.4% in the control group (relative risk 0.67, 95% confidence interval, 0.37–1.21,
p = 0.18) [15]. It must be noted in this connection that arrhythmic death can be
challenging to adjudicate when the patient dies without a witness. However, even
comparing all-cause mortality data did not provide a significant benefit for WCD
patients over those who did not have a WCD [15].
5.7 Renal failure
Compared to one SCD death per 1000 patient-years in the general population,
hemodialysis patients face a 50-fold greater risk of arrhythmic death at 43 deaths
per 1000 patient-years [57, 58]. Patients on hemodialysis present clinical challenges
in that they are often comorbid and frequently geriatric, may be frail, and are prone
to infections. End-stage renal disease and hemodialysis expose these patients to a
very considerable risk of arrhythmic death, but many hemodialysis patients are not
appropriate candidates for ICD therapy. Compared to historical data, the WCD has
been associated with improved survival in renal failure patients [24].
5.8 Other conditions
5.8.1 Takotsubo cardiomyopathy
Takotsubo cardiomyopathy, sometimes called “broken-heart syndrome,” is a
form of cardiomyopathy where the myocardium weakens and remodels. This
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condition is potentially reversible, but while patients experience the cardiomyopa-
thy, they are at risk for potentially life-threatening ventricular tachyarrhythmias,
and some develop concomitant QT interval prolongation, further increasing their
risk for arrhythmia [5]. In a study based on all data from the USA involving WCD
wear from 2007 through 2012, a total of 102 takotsubo patients were identified by
the ICD-9 code 429.83. This population was overwhelmingly female (89%) with an
initial ejection fraction of 27  6% who wore the WCD for a mean duration of
44 31 days with a mean follow-up of 440 374 days. During theWCDwear time,
2% of patients (n = 2) received an appropriate shock, 1% (n = 1) received two
inappropriate shocks, and 2% (n = 2) suffered bradyarrhythmias that required
pacing. Two patients in the study died (one asystole and one from an arrhythmia
while not wearing the WCD) [59].
5.8.2 Peripartum cardiomyopathy
Peripartum cardiomyopathy results in left ventricular dysfunction that can pre-
dispose the patient to SCD. About half of these patients will recover significantly or
entirely over the course of about 6 months even without intervention; however,
some will not, and all are at high risk for arrhythmias during the course of the
condition [5]. In a study of 12 consecutive women with peripartum cardiomyopathy
observed at a single center (of whom seven wore the WCD), four episodes of VF
occurred in three of the patients wearing the WCD, all of which were successfully
terminated. One patient experienced numerous alarms for inappropriate shocks but
was able to abort them so that no inappropriate shocks occurred. No deaths
occurred. During therapy for heart failure, over the course of the 12-month follow-
up, ejection fractions improved significantly from 24.0  11.8% at baseline to
46.6  7.6%. Patients with a lower ejection fraction at baseline improved more than
those with a higher ejection fraction at baseline [60].
5.8.3 Long QT syndrome
Long QT syndrome (LQTS) is a heritable and potentially fatal cardiac
channelopathy that exposes patients to the risk of SCD. LQTS patients are typically
treated with beta blockade, left cardiac sympathetic denervation, and, in some
cases, a permanent ICD. It is unclear what, if any, role the WCD might play for
treating LQTS. A retrospective review of 1027 LQTS patients who were prescribed
a WCD as a bridge to possible ICD implantation or other treatments found no
inappropriate shocks that were administered by the WCD and only 1 patient
received an appropriate shock to terminate VF [61]. Since LQTS is a lifelong
condition, the WCD is not an optimal permanent solution in this population, but it
may be helpful as newly diagnosed patients consider their therapeutic options or
for LQTS patients on medical therapy who are entering high-risk periods of life,
such as having to take a medication that might prolong their QT interval further or
in postpartum women [61].
6. Special populations
The WCD is available in different sizes and has an elasticized waistband and
adjustable straps, making it suitable for use in a variety of patients, including
children. The role of the WCD in certain special populations is being addressed, but
there is limited evidence about these groups.
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6.1 Pediatric patients
Guidance is available to schools and teachers for children prescribed the WCD.
In particular, it is important that educators realize that unlike the automatic external
defibrillator systems available in many schools, the WCD will detect arrhythmias
and treat them without any bystander intervention [62, 63]. Children seem to adjust
well to the WCD. In a study of 231 pediatric WCD patients between the ages of 8
and 17 years monitored a median of 39 days with daily wear time around 21 h/day,
a step-counter accelerometer device reported that activity levels for these
children increased significantly over baseline in the first 3 weeks after getting the
WCD (p < 0.001) [64]. This suggests that the WCD does not inhibit or curtail the
children’s activities and may help them achieve recommended levels of daily exercise.
6.2 Cancer patients
Some patients with cancer may be at elevated risk for dangerous arrhythmias
because of chemotherapy-induced cardiomyopathy or long QT syndrome caused by
drugs but may be contraindicated for device implant because of their malignancy or
other reasons [65].
6.3 Geriatric patients
The prevalence of cardiovascular disease is high in the geriatric population, but
there may be reluctance to consider an older patient for WCD therapy, in particular
because it may be uncomfortable or feel restricting to them. In a large study of 1732
patients with ischemic and nonischemic cardiomyopathy, patients were grouped by
age into younger (<65 years) and older groups (≥65 years). The older group
(n = 722) wore the WCD more hours per day (median 22.8 vs. 22.3, p < 0.001) and
had higher rates of events (31.95 vs. 9.82, p = 0.027). Younger patients with
nonischemic cardiomyopathy had a higher rate of atrial arrhythmias (150.1 vs. 74.9,
p = 0.055), and more following WCD therapy, a greater number of older than
younger patients got a permanent ICD (41.8% vs. 36.5%, p = 0.034). Patients in
both age groups tolerated WCD therapy well [34].
7. Appropriate and inappropriate therapy
TheWCD has been shown to deliver appropriate high-energy therapy to convert
dangerous ventricular tachyarrhythmias. In a postmarket registry of 3569 WCD
patients (mean duration wear was 52.6  69.9 days), first shock success occurred in
99% of cases (79/80) for all episodes of conscious VT/VF and in 100% of cases
(n = 76) of unconscious VT/VF [33]. Because theWCD is an external device, it is far
more exposed to sources of electromagnetic interference (noise) than implanted
devices, which may result in oversensing, inappropriate arrhythmia detection, and
inappropriate therapy delivery. Patients are signaled about 30 s prior to therapy
delivery and may abort the shock by pressing two buttons [39, 40]. For this reason,
the rate of inappropriate therapy delivery with theWCD is relatively low, occurring
in approximately 0.4–3.0% of patients [6, 18, 33, 43]. See Table 1.
The WCD delivers rescue shock therapy only and has no pacing capability.
Asystole, a recognized risk factor for dangerous ventricular tachyarrhythmias, may
occur in patients with compromised cardiovascular function, such as low ejection
fraction. While an ICD can detect and offer pacing support during an asystole
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episode, the WCD cannot pace such patients, and there is a risk that an untreated
asystole may be fatal [66].
8. Patient factors
There are specific patient factors that warrant consideration when prescribing
this novel therapeutic option. Many patients will have no concept of what a WCD is
or how it works.
8.1 Patient education
Manufacturer’s representatives may be available to help train patients in the
proper function of the WCD, and, if they are not available, the clinical team should
make sure the patient knows how to wear the vest, how to adjust it for proper fit,
how to replace the battery, how to charge the battery, and how to transfer data from
the WCD to the network. For this reason, the WCD requires the patient be able to
understand and manage these tasks and be willing to do them. An initial training
session should make sure the patient can put on the vest and insert batteries that
may last an hour or more. It may be helpful for a second follow-up contact with the
trainer over the course of the next few days to help with any questions or problems
the patient may still have. The manufacturer has a 24-h technical support hotline
for urgent questions [5].
8.2 Compliance
Compliance is an issue in all areas of medicine but particularly in the case of the
WCD which patients may find restrictive or uncomfortable. A postmarket registry
study (n = 3569) found that patients who used the WCD for a longer duration of
time (days of wear) were significantly more likely to wear in more hours per day (p
< 0.001) [33]. Over time, theWCD has been redesigned to make it lighter in weight
and more comfortable for extended wear. Remote monitoring can alert the clinic as
to actual wear time for an individual patient [67]. Compliance may be encouraged
by educating the patient as to the nature of ventricular tachyarrhythmias and how
the device protects them.
8.3 Psychological factors
It has been speculated that patients prescribed a WCD may experience emo-
tional distress and view the device as a constant worrisome reminder of their own
mortality. Patients may also feel isolated if they do not know anyone else who has
ever worn such a device. Patients have sometimes reported that they find the device
symbolic of their own vulnerability [33]. Of course, such adverse emotions may
occur in all patients facing the sudden news that they have a serious cardiovascular
condition regardless of whether they are prescribed a WCD or some other therapy.
Psychological distress is an important clinical consideration because it is potentially
modifiable. There may be ways to reduce depressive or anxious symptoms in clin-
ically meaningful ways. Depression worsens outcomes and actually serves as a
predictor for both mortality and shock therapy [68, 69]. Depression has been
associated with a nearly doubled risk for all-cause mortality in ICD patients [69].
Furthermore, depression and anxiety may adversely affect patient compliance,
adherence to pharmacological therapy, and lifestyle.
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In another study of 123 patients considered WCD candidates, at baseline 21%
showed signs of clinically depressive symptoms, and 52% had anxiety. Six weeks
after WCD therapy commenced, rates of depression and anxiety dropped to 7 and
25%, respectively [32]. It is not clear if patients recovered their emotional equilib-
rium as a result of WCD therapy or as a matter of course as they got used to their
new identities as cardiac patients.
8.4 Device-device compatibility
When a patient has more than one electronic cardiac device, the potential of
device-device interaction exists. The literature reports one case of a fatal device-
device interaction between a permanent pacemaker and a WCD [70]. In this case,
the patient received unipolar dual-chamber pacing, but when he developed VF, no
therapy was delivered as the device inappropriately detected the large unipolar
pacing spikes as cardiac signals [70].
A study sponsored by Zoll examined pacing in 60 patients testing the AAI,
VVI, and DDD modes in both unipolar and bipolar device configurations to
determine if the WCDwould detect the pacing spikes; patients were signaled before
shock delivery and could use the patient response buttons to avert the therapy
delivery. Only unipolar DDD pacing was detected by the WCD’s algorithm and
only in 10% of patients (6/60). This study suggests that pacing may occur
concomitantly with WCD use if unipolar configurations are avoided [2]. If unipolar
pacing must be used in a particular patient, then the WCD is contraindicated.
Another study of the concomitant use of the WCD and a pacemaker showed that
double-counting and waveform alterations might also occur in certain bipolar
pacing modes and in single-chamber as well as dual-chamber pacing [44].
Caution is urged in using the WCD in patients with pacing support from an
implanted pacemaker system.
9. Costs
The WCD is “rented” to patients for a monthly fee, and reimbursement
provisions vary by country. Since costs can be substantial, there is a need to better
stratify patients into those who truly need a WCD for arrhythmic rescue and
those who might be unlikely to benefit from it [41]. Cost-effectiveness models show
that the number needed to treat to save 1 life with a WCD falls in the range of
70–110 patients over a median of 53–57 days [26]. There are situations in which the
WCD poses a decided cost advantage. For example, cardiomyopathy patients who
might otherwise be considered a candidate for permanent primary prevention ICD
implantation may benefit from using the WCD during a recovery period; data
shows that 60% of such patients will recover to the point that an ICD
implantation is not necessary [18, 33, 41]. Thus, the costs for the temporary use of
the WCD may be offset by the decision not to implant an ICD. In patients whose
ICD must be removed for infection, it is sometimes necessary to keep the patient in
the hospital or discharge him or her to a skilled nursing facility for weeks
during antimicrobial therapy and recovery. The patient is at risk for SCD
throughout this time. A cost-effectiveness analysis found that the WCD was cost-
effective in this situation in that it allowed the patient to be discharged home;
the analysis is based on the assumption that there was a 2-week 5.6% risk of SCD
in the population and the patient had to wait at least 2 weeks before ICD
replacement [71].
19
The Wearable Cardioverter-Defibrillator
DOI: http://dx.doi.org/10.5772/intechopen.90663
10. Future directions
The WCD technology effectively treats VT/VF, but bradycardia pacing support
would likely prevent SCD to an even greater extent. Adding pacing capability to the
WCD would be an important and life-saving step forward.
A major obstacle in WCD therapy remains patient adherence. Unfortunately,
not all patients are motivated to comply with the prescription to use the WCD, and
unnecessary deaths occur because of poor compliance. Therefore, motivating the
patient to adhere to therapy is of utmost importance. A combined approach with
technology reminders (e.g., text messages via smartphones) and close follow-up by
device professionals is crucial.
Much has been accomplished in the past 30 years to better treat the risk of SCD,
and the WCD is definitely an important milestone in our advancing knowledge.
Nevertheless, much more needs to be done to reduce the rates of arrhythmic death
even more.
A Class II recall of the WCD occurred in January 2018, covering 33,000 devices.
This problem, in which certain vests displayed a warning message to the effect that
they could not charge sufficiently to deliver therapy, has been addressed.
11. Conclusions
The WCD is an important advancement in the armamentarium for cardiovas-
cular disease and demonstrates safe, effective therapy, but patient compliance
remains a concern. The WCD is an interim therapeutic alternative to the ICD. In
some cases, the WCD may help patients recover significant systolic function to the
point that an ICD is no longer necessary. Patients who need the WCD should
receive individual one-on-one instruction in how to use the device, and clinicians
should be prepared that there may be a degree of psychological distress. Neverthe-
less, these devices are important advancement in cardiac care for people at risk of
dangerous arrhythmias.
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